Robert Geho is a Co-Founder and CEO of Diasome Pharmaceuticals, Inc., a company with targeted insulin therapies, novel Type 2 Diabetes technology, and oral therapy for obesity. He is concurrently the Co-Founder and Director of SDG, Inc., a Nanotechnology Therapeutics company an Equity Partner Company of the Cleveland Clinic Foundation located in Cleveland, Ohio. Geho was diagnosed with Type 1 Diabetes more than twenty years ago. He has been actively involved in the development of strategies for explaining the role of the liver in glucose metabolism and its ability to regulate glucose in people with Diabetes. He received both his undergraduate degree and an MBA from Case Western Reserve University. Robert also serves as a member on the boards of directors to the Diabetes Hands Foundation in Berkeley, CA and the Intermuseum Conservation Association in Cleveland, OH.